{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Abbreviations', 'Description of abbreviations', 'EORTC', 'European Organisation for Research and Treatment of Cancer', 'EOT', 'end of treatment', 'ePRO', 'electronic patient reported outcome', 'EQ-5D-5L', 'EuroQOL 5-dimensions', 'EV', 'enfortumab vedotin', 'FAS', 'full analysis set', 'FDA', 'Food and Drug Administration', 'GCP', 'good clinical practice', 'GFR', 'glomerular filtration rate', 'GGT', 'gamma-glutamyl transferase', 'GMP', 'good manufacturing practice', 'HbA1c', 'Hemoglobin Alc', 'HBsAg', 'hepatitis B surface antigen', 'Hct', 'hematocrit', 'HCV', 'hepatitis C virus', 'Hgb', 'hemoglobin', 'HIPAA', 'health insurance portability and accountability act', 'HIV', 'human immunodeficiency virus', 'HRU', 'healthcare resource utilization', 'IARC', 'International Agency for Research on Cancer', 'IB', \"Investigator's Brochure\", 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonisation', 'IDAC', 'Independent data analysis center', 'IDMC', 'Independent data monitoring committee', 'IEC', 'independent ethics committee', 'IND', 'investigational new drug', 'INR', 'international normalized ratio', 'IRB', 'institutional review board', 'IRR', 'infusion-related reaction', 'IRT', 'interactive response technology', 'ITT', 'Intent to treat', 'ISN', 'international study number', 'IUD', 'intrauterine device', 'IUS', 'intrauterine hormone releasing system', 'LA-CRF', 'liver abnormality case report form', 'LFT', 'liver function test', 'MMAE', 'monomethyl auristatin E', 'MRI', 'magnetic resonance imaging', 'MTD', 'maximum tolerated dose', 'mUC', 'metastatic urothelial cancer', 'MVAC', 'methotrexate, vinblastine, doxorubicin, and cisplatin', '14 Sep 2020', 'Astellas', 'Page 14 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Abbreviations', 'Description of abbreviations', 'NCI-CTCAE', \"National Cancer Institute's Common Terminology Criteria for Adverse Events\", 'NOAEL', 'no observed adverse effect level', 'ORR', 'overall response rate', 'OS', 'overall survival', 'PBMC', 'peripheral blood mononuclear cells', 'PD', 'progressive disease', 'PDAS', 'pharmacodynamics analysis set', 'PD-1', 'programmed cell death protein 1', 'PD-L1', 'programmed death-ligand 1', 'PFS', 'progression free survival', 'P-gp', 'p-glycoprotein', 'PGx', 'pharmacogenomics analyses', 'PKAS', 'pharmacokinetic analysis set', 'PR', 'partial response', 'PRES', 'posterior reversible encephalopathy syndrome', 'PRO', 'patient reported outcome', 'QLQ-C30', 'EORTC Quality of Life Questionnaire', 'QOL', 'quality of life', 'RBC', 'red blood cell', 'RECIST', 'Response Evaluation Criteria in Solid Tumors', 'RES', 'response evaluable set', 'ROW', 'rest of the world', 'SAE', 'serious adverse event', 'SAF', 'safety analysis set', 'SAP', 'statistical analysis plan', 'SD', 'stable disease', 'SmPC', 'Summary of product characteristics', 'SOP', 'standard operating Procedure', 'Tab', 'total antibody', 'TBL', 'total bilirubin', 'TEAE', 'treatment emergent adverse events', 'TMF', 'trial master file', 'TP', 'total protein', 'ULN', 'upper limit of normal', 'US', 'United States', 'WBC', 'white blood cell', '14 Sep 2020', 'Astellas', 'Page 15 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}